Germany kava decision
This article was originally published in The Tan Sheet
Executive Summary
Roughly 40 companies, 80 products affected by decision of Germany's Federal Institute for Drugs & Medical Devices (BfArM) to cancel registrations for kava products. June 14 ban is appealable, first to BfArM and then to court. BfArM notified German kava manufacturers last November of its intent to study adverse event reports related to the botanical (1"The Tan Sheet" Dec. 3, 2001, p. 8)...
You may also be interested in...
Kava Safety Reconsidered In Germany, FDA/Trade Associations Take Note
FDA is reconsidering kava's safety following reports the German government might ban its sale due to a possible link between the botanical and liver toxicity
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.